Both forms of Wegovy carry risks of rare but more severe issues, such as: Thyroid C-cell tumors Multiple endocrine neoplasia type-2 Pancreatitis Gallbladder disease Hypoglycemia As of now, no credible data indicate that the Wegovy pill poses a more serious risk for any of these rare complications than the injectable
Comparable observations have been noted in humans, with exogenous L-carnitine supplementation having a positive impact on immune mediators, showing its beneficial effects in preventing infection 5
Third, it causes nausea in a meaningful percentage of users, particularly during the first few weeks of treatment
"If it is not broken, do not fix it" applies here
For women with existing thyroid conditions, such as hypothyroidism managed with levothyroxine, GLP-1 medications dont directly interact with thyroid hormone replacement